Abstract
Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30 ± 0.24 mm in abciximab-coated stent group and 29%, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4%) vs. BMS: n = 4 (6%), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.
| Original language | English |
|---|---|
| Pages (from-to) | 23-28 |
| Number of pages | 6 |
| Journal | International Journal of Cardiology |
| Volume | 123 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2007 Dec 15 |
| Externally published | Yes |
Fingerprint
Keywords
- Coronary artery diseases
- Intravascular ultrasound
- Platelets
- Stents
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation : An intravascular ultrasound analysis. / Hong, Young Joon; Jeong, Myung Ho; Hwang, Sun Ho; Yun, Nam Sik; Lim, Sang Yeob; Lee, Sang Rok; Hong, Seo Na; Kim, Kye Hun; Park, Hyung Wook; Kim, Ju Han; Kim, Weon; Ahn, Young Keun; Cho, Jeong Gwan; Park, Jong Chun; Kang, Jung Chaee.
In: International Journal of Cardiology, Vol. 123, No. 1, 15.12.2007, p. 23-28.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation
T2 - An intravascular ultrasound analysis
AU - Hong, Young Joon
AU - Jeong, Myung Ho
AU - Hwang, Sun Ho
AU - Yun, Nam Sik
AU - Lim, Sang Yeob
AU - Lee, Sang Rok
AU - Hong, Seo Na
AU - Kim, Kye Hun
AU - Park, Hyung Wook
AU - Kim, Ju Han
AU - Kim, Weon
AU - Ahn, Young Keun
AU - Cho, Jeong Gwan
AU - Park, Jong Chun
AU - Kang, Jung Chaee
PY - 2007/12/15
Y1 - 2007/12/15
N2 - Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30 ± 0.24 mm in abciximab-coated stent group and 29%, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4%) vs. BMS: n = 4 (6%), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.
AB - Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30 ± 0.24 mm in abciximab-coated stent group and 29%, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4%) vs. BMS: n = 4 (6%), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.
KW - Coronary artery diseases
KW - Intravascular ultrasound
KW - Platelets
KW - Stents
UR - http://www.scopus.com/inward/record.url?scp=36148977184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36148977184&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2006.11.101
DO - 10.1016/j.ijcard.2006.11.101
M3 - Article
VL - 123
SP - 23
EP - 28
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 1
ER -